Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 3;10:809061. doi: 10.3389/fped.2022.809061

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 van der Velden, van Delft, Owens, Llevadias, McKean, Pulford, Taha, Williamson, Campbell-Hewson, Hambleton, Payne, Duncan, Johnston, Spegarova and Emonts.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

A schematic overview of respiratory and immunomodulatory management over time. (A) Overview of respiratory support and medical interventions over time. Day 0 is the day of autologous stem cell infusion and the day the patient first tested positive for SARS-CoV-2. (B) Overview of inflammatory markers and neutrophil and lymphocyte counts over time. Day 0 is the day of autologous stem cell infusion. ETT/BAL, endotracheal/bronchoalveolar lavage secretions; NTS, nose–throat swab; ANC, absolute neutrophil count; CRP, C-reactive protein; PCT, procalcitonin. (C) CD4 lymphocytes and naïve T-cell counts over time. Day 0 is the day of autologous stem cell infusion.